Meta-analysis of Efficacy and Safety of Interleukin-6 Inhibitor Sirukumab for Treatment of Rheumatoid Arthritis

OBJECTIVE To assess the efficacy and safety of interleukin-6(IL-6) inhibitor of Sirukumab for rheumatoid arthritis(RA). METHODS All randomized controlled trials(RCTs) about the efficacy and safety of treating RA by Sirukumab were searched and retrieved from the databases including PubMed, Embase, Web of Science, Clinical Trials Website, Cochrane Library, CNKI, WanFang, and VIP database. Meta-analysis of the datas were performed by RevMan 5.3 software. RESULTS Included 6 RCTs with 3 197 patients. Compared with placebo, the effective rate of ACR20, ACR50 and ACR70 in the both doses groups of Sirukumab were higher(P<0.000 1). And the same with the incidence rate of adverse reactions, serious adverse events, serious infections, injection site reactions and termination of trial due to adverse reactions in Sirukumab group were higher(P<0.05). Compared with Adalimumab, the effective rate of DAS28-ESR in the both dose groups of Sirukumab were higher(P<0.05). There was no statistically significant difference in the ACR50 between the Sirukumab group and the Adalimumab group(P>0.05). CONCLUSION Available evidences suggest that Sirukumab is safe and effective in treating RA. Limited by the number of included references, the above conclusions require further high-quality clinical trials to evaluate the effectiveness and safety.